Alligator Bioscience

We are an innovative clinical-stage biotechnology company developing tumor-directed immunotherapies for the treatment of cancer.

[BioStock @BioStock_SWE]

Alligator Bioscience’s Q3 is out – comments from the CEO #LifeSciences #BioStockSwe @AlligatorBio https://t.co/q9v3nGLW93

[LifeSci Advisors @LifeSciAdvisors]

Tune into Episode 55 of the Benchtop Bios Podcast Series, featuring Søren Bregenholt, CEO of @AlligatorBio, who will discuss Alligator’s latest clinical data in the development of tumor-directed immunotherapies. Listen here: https://t.co/e0RA66Qz8Q

[Alligator Bioscience @AlligatorBio]

Opportunity to join Alligator Bioscience! https://t.co/D71V2uC9Ra

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update https://t.co/libytuBgbP

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022 https://t.co/BoXnvi5fQJ

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience expands its Board of Directors with the appointment of Staffan Encrantz and Denise Goode https://t.co/n6HDpFgni8

[Alligator Bioscience @AlligatorBio]

Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022 https://t.co/N6SqC5ZwP9

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience AB: Interim report January–March 2022 https://t.co/HbqmxvOlRA

[Alligator Bioscience @AlligatorBio]

Invitation to the Presentation of Alligator Bioscience´s Interim Report January - March 2022 on April 27, 2022 https://t.co/6KlMTNfPpV

[Alligator Bioscience @AlligatorBio]

Notice of annual general meeting in Alligator Bioscience AB https://t.co/Ot3ZFq2MCy

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences https://t.co/EE8m92uorC

[Alligator Bioscience @AlligatorBio]

Change in number of shares and votes in Alligator Bioscience AB https://t.co/5IlGYR74AZ

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg https://t.co/ttHF5X8qGZ

[Alligator Bioscience @AlligatorBio]

Issue and repurchase of series C shares for performance-based share saving program https://t.co/E0yHoGjwNz

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience publishes Annual Report for 2021 https://t.co/UeiefIB2QZ

[Alligator Bioscience @AlligatorBio]

Nomination Committee’s proposal ahead of the AGM 2022 in Alligator Bioscience AB

[Alligator Bioscience @AlligatorBio]

Invitation to the Presentation of Alligator Bioscience´s Year-End Report January - December 2021 on February 11, 2022 https://t.co/zdBny5ZDxN

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer https://t.co/My0Q7b31Kl

[Alligator Bioscience @AlligatorBio]

Nomination Committee Appointed in Respect of AGM 2022 in Alligator Bioscience AB https://t.co/I7PjC56kal

[Alligator Bioscience @AlligatorBio]

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty https://t.co/1DEH7Q7QgG